Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook.
- DOI
- 10.21037/atm-21-2804
- Published
- 2021 Jul
- Container
- Annals of translational medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/atm-21-2804,
title = {Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook.},
author = {Jin Z and Shen J and Wang C and Chen D and Zhang B and Zhang J and Ajani JA and Bennouna J and Chao J and Yoon HH and Zhu H and Ruan Y and Zhu C and Xu A},
year = {2021},
journal = {Annals of translational medicine},
doi = {10.21037/atm-21-2804},
url = {https://doi.org/10.21037/atm-21-2804}
}RIS
TY - JOUR TI - Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. AU - Jin Z AU - Shen J AU - Wang C AU - Chen D AU - Zhang B AU - Zhang J AU - Ajani JA AU - Bennouna J AU - Chao J AU - Yoon HH AU - Zhu H AU - Ruan Y AU - Zhu C AU - Xu A PY - 2021 JO - Annals of translational medicine DO - 10.21037/atm-21-2804 UR - https://doi.org/10.21037/atm-21-2804 ER -
APA
Z, J., J, S., C, W., D, C., B, Z., J, Z., JA, A., J, B., J, C., HH, Y., H, Z., Y, R., C, Z., & A, X. (2021). Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook.. Annals of translational medicine. https://doi.org/10.21037/atm-21-2804
Source records
- pubmed · retrieved 2026-09-25T13:03:18.627Z